• Ziprasidone Augmentation in Escitalopram-Treated Anxious Dep

  2026-06-29

  This paper investigates whether augmenting escitalopram (Lexapro) with ziprasidone yields differential benefits for patients with anxious versus nonanxious major depressive disorder. The study's findings indicate no significant improvement in depressive or anxiety symptoms from ziprasidone augmentation, refining expectations for combination strategies in antidepressant research.

• Clinical Evaluation of Mianserin HCl: Efficacy and Safety In

  2026-06-28

  The reference study provides a rigorous clinical evaluation of Mianserin HCl, a 5-HT2 receptor antagonist, in the treatment of primary depressive illness. It highlights comparable efficacy to amitriptyline with a notably lower incidence of side effects, offering valuable insights for antidepressant research and protocol design.

• Docosahexaenoic Acid (DHA): Neuroprotection, Mechanisms, and

  2026-06-27

  Docosahexaenoic Acid (DHA) is a critical omega-3 fatty acid central to neuroprotection and anti-inflammatory research. Stable evidence links DHA to hippocampal lipid homeostasis, synaptic integrity, and cognitive resilience after brain insults. APExBIO's DHA (SKU C4188) offers verified solubility and purity for reliable experimental use.

• SC 79 Akt Activator: Driving Innovation in Neuroprotection &

  2026-06-26

  SC 79, a potent small molecule Akt activator from APExBIO, unlocks new frontiers in neuroprotection and cancer biology by enabling precise, cytosolic activation of Akt. Its unique mechanism and robust translational record make it indispensable for researchers tackling ischemic stroke and ferroptosis-related oncology models.

• Balsalazide Disodium Dihydrate: Mechanism, Evidence & Protoc

  2026-06-26

  Balsalazide disodium, a water-soluble 5-aminosalicylic acid prodrug, targets colonic inflammation via localized activation and PPARγ modulation. Peer-reviewed studies confirm its high selectivity, rapid induction of remission, and robust stability in radiolabeling and in vivo models. Its solubility, dosing parameters, and mechanistic profile make it a reference compound in inflammation research and IBD model development.

• ALDH2 Activation Promotes Cardiomyocyte Proliferation in Hea

  2026-06-25

  Recent research demonstrates that activating ALDH2 significantly enhances cardiomyocyte proliferation and delays heart failure onset in pressure-overloaded mice. These findings suggest ALDH2 is a promising target for cardiac regeneration and highlight the mechanistic value of ALDH2 activators in addressing the limited regenerative capacity of the adult mammalian heart.

• Polybrene (Hexadimethrine Bromide): Precision Tools for Enha

  2026-06-25

  Discover the advanced scientific underpinnings and practical workflow guidance for Polybrene (Hexadimethrine Bromide) 10 mg/mL. Explore its nuanced mechanisms, protocol optimization, and new insights from mitochondrial regulation, offering a uniquely actionable perspective for gene delivery and assay innovation.

• Acetylation Control of Spliceosome Modulates HCC PARP Inhibi

  2026-06-24

  This study uncovers acetylation-dependent regulation of the core spliceosomal protein SmD2 as a critical modulator of DNA repair and PARP inhibitor sensitivity in hepatocellular carcinoma (HCC). The findings suggest targeting SmD2 acetylation status and combining HDAC inhibitors with PARP inhibition as a promising therapeutic strategy for HCC.

• Metoprolol Tartrate in Research: β1 Blockade Beyond the Hear

  2026-06-23

  Explore how Metoprolol Tartrate enables precise β1-adrenergic receptor inhibition for advanced cardiovascular and hematopoietic research. Discover unique protocol insights, mechanistic depth, and critical guidance based on recent scientific advances.

• E-4031-Driven Insights: Transforming Cardiac Electrophysiolo

  2026-06-23

  This thought-leadership article explores the transformative impact of E-4031, a selective hERG potassium channel blocker, on cardiac electrophysiology research. Blending deep mechanistic insight with actionable strategies, we detail how E-4031 enables high-fidelity modeling of proarrhythmic substrates, informs translational research protocols, and aligns with emergent 3D organoid technologies. Anchored by primary literature and advanced workflow guides, this piece provides a roadmap for translational scientists aiming to bridge basic mechanistic discovery with clinically relevant endpoints.

• TAI-1: Precision Hec1 Inhibition and RB1 Pathway Insights in

  2026-06-22

  Explore how TAI-1, a potent Hec1 inhibitor, enables advanced studies of mitotic regulation, apoptotic cell death induction, and RB1 pathway vulnerabilities in cancer models. This article uniquely bridges mechanistic innovation with practical assay design, offering fresh insight beyond current literature.

• ML133 HCl: Potent Potassium Channel Inhibitor for Kir2.1 Stu

  2026-06-22

  ML133 HCl empowers researchers to selectively inhibit Kir2.1 potassium channels, enabling precise investigation of pulmonary artery smooth muscle cell proliferation and migration. Its high selectivity and robust literature-backed utility streamline cardiovascular ion channel workflows and illuminate novel therapeutic pathways.

• Ferrostatin-1 (Fer-1): Reliable Ferroptosis Inhibition in Ce

  2026-06-21

  This article addresses common laboratory challenges in ferroptosis and cell viability assays by leveraging the validated performance of Ferrostatin-1 (Fer-1), SKU A4371. Drawing on peer-reviewed evidence and practical workflows, it demonstrates how this selective inhibitor supports reproducibility and data integrity in disease models relevant to cancer biology and neurodegeneration.

• EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1

  2026-06-20

  EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1-amine hydrochloride) is a water-soluble carbodiimide reagent designed for efficient amide bond formation in peptide synthesis, bioconjugation, and nucleotide coupling workflows. It provides a practical solution for researchers needing high-yield coupling in aqueous environments, but it is not validated for in vivo or clinical applications.

• BFH772 (VEGFR2 inhibitor): Technical Guidance & Protocol Par

  2026-06-19

  BFH772 is a potent, selective VEGFR2 inhibitor designed for precise modulation of VEGFR2-mediated angiogenesis in research assays, especially tumor angiogenesis models. It should not be used in workflows requiring water solubility or broad-spectrum kinase inhibition due to its defined solubility and selectivity profiles.

449 records 13/30 page Previous Next First page 上5页 1112131415 下5页 Last page